Phase 3 N=225 Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure
Chronic Heart Failure
Primary: Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption) — 28.04; 3.90 mL/min — p=0.4570
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=501 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Number of Treatment Emergent Severe or BG (Blood Glucose) Confirmed Symptomatic Hypoglycaemic Episodes During the Maintenance Period — 2772; 3126 Event — p=<0.0001
Phase 3 N=808 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Stage I Kidney Wilms Tumor · Stage II Kidney Wilms Tumor · Stage III Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.88; 0.87; 0.88 Probability
Phase 3 N=435 Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
Anemia · Chronic Kidney Disease (CKD)
Primary: Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28) — -0.0960; -0.0035 g/dL
Phase 3 N=311 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
Lower Limb Spasticity Due to Cerebral Palsy
Primary: Change From Baseline in the Ashworth Scale (AS) Score of Plantar Flexors of the Primary Body Side at Day 29 (Week 4) of the First Injection Cycle (1st IC) — -0.7; -0.66…
Phase 3 N=1,163 A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Primary: Part A Treatment Cohort: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 331; 177; 333; 176 participants
Phase 3 N=275 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia · L1 Childhood Acute Lymphoblastic Leukemia · L2 Childhood Acute Lymphoblastic Leukemia
Primary: Event Free Survival. EFS — 66.0 percentage of participants EFS at 3 yrs3
Phase 3 N=125 Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm — 117; 27 participants
Phase 3 N=668 Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
Advanced, Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) by Investigator Assessment — NA; 14.7 months — p=0.00000329
Phase 3 N=251 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Sporadic Inclusion Body Myositis
Primary: Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52 — 8.63; 9.63; -10.27; -8.96 meters — p=0.2210
Phase 3 N=709 Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
HIV
Primary: Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study…
Phase 3 N=590 Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE) — 71.4; 65.7 Percentage of participants
Phase 3 N=4 A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes
Type 2 Diabetes
Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 12 (Last Observation Carried Forward [LOCF]) - Cohort 2 — 0.09; -0.61; -0.69 % of hemoglobin
Phase 3 N=104 D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Wisconsin Card Sorting Test (WCST) — 38.43; 35.79; 43.14; 39.57 percentage of correct responses
Phase 3 N=153 Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 96.6; 96.3 percentage of participants